Trials / Completed
CompletedNCT04053699
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
A Prospective, Multicenter, Non-Interventional Study Evaluating the Bleeding Incidence in Patients With Von Willebrand Disease Undergoing On-Demand Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 56 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 66 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months. The data obtained will be used as a basis for historical comparisons with the bleeding and treatment pattern obtained from a clinical study on the efficacy of prophylactic treatment with a VWF/FVIII concentrate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Von Willebrand Factor-Containing Product | Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country |
Timeline
- Start date
- 2019-06-25
- Primary completion
- 2021-01-31
- Completion
- 2021-01-31
- First posted
- 2019-08-12
- Last updated
- 2023-12-07
- Results posted
- 2023-12-07
Locations
15 sites across 8 countries: United States, Belarus, Bulgaria, Croatia, Hungary, Lebanon, Russia, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04053699. Inclusion in this directory is not an endorsement.